Medix Biochemica launches refreshed and expanding brand

1st Mar 2022

Medix Biochemica is launching a rejuvenated brand to reflect both the exciting improvements to its offering as a result of recent acquisitions, and its ongoing commitment to the in vitro diagnostics (IVD) industry.

Medix Biochemica acquires myPOLS Biotec

1st Feb 2022

Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH, a German manufacturer of innovative and high-quality raw materials in molecular diagnostics.

Delivering IVD raw material expertise in China for 5 years

16th Nov 2021

This year marks the fifth anniversary of Medix Biochemica in China. Over the past five years, Medix Biochemica China, and China’s IVD industry have undergone significant changes and developments.

Discover new study findings of Serum Amyloid A mAbs

30th Sep 2021

Medix Biochemica presented the findings of a study ‘Monoclonal Serum Amyloid A antibodies applicable to human and veterinary diagnostic immunoassays with wide detection ranges’ in 2021 AACC exhibition in Atlanta, on September 28th.

Medix Biochemica acquires Diaclone

13th Jul 2021

Medix Biochemica has acquired 100 percent of the shares of Diaclone, a prominent provider of monoclonal antibodies in the areas of inflammation, oncology, and immunology.

Discover our latest products

9th Jul 2021

We are pleased to announce a further expansion of our portfolio with the introduction of several new products for the development of diagnostic assays: